Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Sees Large Decrease in Short Interest

Key Points

• Short interest in Autolus Therapeutics decreased by 32.1% in August, totaling 10,110,000 shares, indicating a shift in investor sentiment.
• Analysts have mixed views on the stock, with five analysts rating it as a "Buy" and an average price target of $9.12, while Wells Fargo & Company has downgraded their price target from $6.00 to $5.00.
• Autolus reported earnings of ($0.18) per share, surpassing expectations and generating revenue of $13.50 million for the quarter.

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Get Free Report) saw a large decline in short interest in August. As of August 31st, there was short interest totaling 10,110,000 shares, a decline of 32.1% from the August 15th total of 14,900,000 shares. Approximately 5.1% of the company's shares are short sold. Based on an average trading volume of 2,590,000 shares, the days-to-cover ratio is presently 3.9 days. Based on an average trading volume of 2,590,000 shares, the days-to-cover ratio is presently 3.9 days. Approximately 5.1% of the company's shares are short sold.

Wall Street Analyst Weigh In

Several research firms recently issued reports on AUTL. Wall Street Zen raised shares of Autolus Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 16th. Wells Fargo & Company cut their price target on shares of Autolus Therapeutics from $6.00 to $5.00 and set an "overweight" rating on the stock in a report on Wednesday, August 13th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $10.00 price target on shares of Autolus Therapeutics in a research report on Monday, July 21st. Five analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Autolus Therapeutics currently has an average rating of "Buy" and an average target price of $9.12.

Autolus Therapeutics Trading Down 1.5%

AUTL traded down $0.02 during trading on Friday, reaching $1.34. The stock had a trading volume of 3,620,189 shares, compared to its average volume of 4,457,506. The stock's 50 day moving average is $1.94 and its two-hundred day moving average is $1.81. The company has a market capitalization of $356.63 million, a price-to-earnings ratio of -1.60 and a beta of 1.87. Autolus Therapeutics has a one year low of $1.11 and a one year high of $5.00.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.24) by $0.06. The firm had revenue of $13.50 million during the quarter, compared to the consensus estimate of $12.92 million. On average, equities research analysts predict that Autolus Therapeutics will post -0.94 earnings per share for the current year.

Hedge Funds Weigh In On Autolus Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of AUTL. Wellington Management Group LLP boosted its position in shares of Autolus Therapeutics by 6.9% during the first quarter. Wellington Management Group LLP now owns 27,091,700 shares of the company's stock valued at $41,992,000 after buying an additional 1,746,020 shares during the last quarter. Armistice Capital LLC boosted its position in Autolus Therapeutics by 9.1% in the second quarter. Armistice Capital LLC now owns 12,000,000 shares of the company's stock worth $27,360,000 after purchasing an additional 1,000,000 shares during the last quarter. TFG Asset Management GP Ltd lifted its position in shares of Autolus Therapeutics by 10.5% during the 2nd quarter. TFG Asset Management GP Ltd now owns 9,500,000 shares of the company's stock valued at $21,660,000 after buying an additional 900,000 shares in the last quarter. Millennium Management LLC lifted its position in shares of Autolus Therapeutics by 91.6% during the 4th quarter. Millennium Management LLC now owns 1,653,241 shares of the company's stock valued at $3,885,000 after buying an additional 790,437 shares in the last quarter. Finally, Atle Fund Management AB lifted its position in shares of Autolus Therapeutics by 130.5% during the 2nd quarter. Atle Fund Management AB now owns 1,105,461 shares of the company's stock valued at $2,520,000 after buying an additional 625,817 shares in the last quarter. 72.83% of the stock is currently owned by institutional investors.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.